Baxdrostat meets primary & all secondary endpoints in BaxHTN phase III trial for hypertension

Overview

Positive high-level results from the BaxHTN phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favourable safety profile.

Hypertension epidemiology

• There are 1.3 billion people worldwide living with hypertension. When uncontrolled, hypertension can lead to a higher risk of heart attack, stroke, heart failure and kidney disease. 
• In the US, approximately 50% of hypertensive patients who are on multiple treatments do not have their blood pressure under control. 
• Growing evidence points to aldosterone dysregulation as one of the key biological drivers of hypertension.

Statement from Dr. Bryan Williams: primary investigator od trial

Dr. Bryan Williams, Chair of Medicine at University College London, primary investigator, said: “Many people continue to struggle with high blood pressure that is hard to control, even when taking multiple medications. The highly promising BaxHTN phase III results show that once-daily baxdrostat on top of standard of care can meaningfully lower systolic blood pressure and offer a potential new treatment approach for controlling hypertension, the leading risk factor for cardiovascular disease.”

Statement from Sharon Barr, executive vice president, biopharmaceuticals R&D

Sharon Barr, executive vice president, biopharmaceuticals R&D, said: “We are very excited with the BaxHTN phase III results, which show statistically significant and clinically meaningful reductions in systolic blood pressure. These findings provide compelling evidence of baxdrostat’s potential to address a critical unmet need by targeting aldosterone dysregulation, bringing a novel mechanism to a field that has seen little innovation in over two decades.”

Phase III trial for BaxHTN

• BaxHTN is a phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of baxdrostat in patients with uncontrolled hypertension being treated with two different antihypertensive medications and patients with resistant hypertension being treated with three or more different antihypertensive medications, one of which is a diuretic.
• The data will be shared with regulatory authorities around the world and presented in a late-breaking Hot Line session at the European Society of Cardiology (ESC) Congress in August 2025.

Baxdrostat Targets Hypertension and Kidney Disease

• Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor (ASI) that targets the hormone driving elevated blood pressure and increased cardiovascular and renal risk. 
• It is currently being investigated in clinical trials as a monotherapy for hypertension and primary aldosteronism, and in combination with dapagliflozin for chronic kidney disease and the prevention of heart failure in high-risk hypertensive patients.

Hypertension & its causes

• Hypertension is a medical condition characterised by consistently high blood pressure levels. Over time, this can damage blood vessels and vital organs, increasing the risk of serious health problems. Hypertension that is hard to control remains a significant public health challenge. 
• Despite lifestyle changes and the use of multiple medications, a significant majority of people with hypertension do not achieve their blood pressure goals. 
• Uncontrolled hypertension persists despite treatment with two or more medications, while resistant hypertension, a more severe form, remains elevated despite treatment with three or more medications. 
• A key contributor of hypertension that is hard to control is aldosterone, a hormone that increases blood pressure by promoting sodium and water retention. Elevated aldosterone levels, along with factors like obesity, high salt intake and various genetic and secondary conditions, are strongly linked to poor blood pressure control. If left untreated, the condition significantly increases the risk of heart attack, stroke and kidney decline.

About The BaxHTN phase III trial

• The BaxHTN phase III trial had three components to it that support the following endpoints: The primary endpoint was assessed during a 12-week double-blind, placebo-controlled period. 
• A total of 796 patients were randomised in a 1:1:1 ratio to receive baxdrostat 2mg, 1mg or placebo once daily. 
• The primary efficacy endpoint was the difference in mean change from baseline in seated SBP at Week 12 between participants treated with baxdrostat (2mg or 1mg separately) and participants treated with placebo. 
• Persistence of efficacy was assessed during a randomised withdrawal period from week 24 to week 32. 
• Approximately 300 patients treated with baxdrostat 2mg were re-randomised in a 2:1 ratio to either continue receiving baxdrostat 2mg or placebo for the 8 weeks. 
• SBP at the end of the 8 weeks was compared with placebo and the baxdrostat 2mg dose. Long-term safety is assessed at the end of the 52 weeks compared to a standard of care arm.
• Additional secondary endpoints include the effect of baxdrostat versus placebo on seated SBP at Week 12 in the resistant hypertension subpopulation, the effect of baxdrostat versus placebo on seated diastolic blood pressure at Week 12, participants achieving seated SBP less than 130 mmHg at Week 12 and occurrence of adverse events.

About the drug: Baxdrostat

• Baxdrostat is a potential first-in-class, highly selective and potent, oral, small molecule that inhibits aldosterone synthase, an enzyme encoded by the CYP11B2 gene, which is responsible for the synthesis of aldosterone in the adrenal gland. 
• In clinical trials, baxdrostat was observed to significantly lower aldosterone levels without affecting cortisol levels across a wide range of doses. 
• Baxdrostat is currently being investigated in clinical trials as a monotherapy for hypertension and primary aldosteronism, and in combination with dapagliflozin for chronic kidney disease and the prevention of heart failure in hypertensive patients.

Baxdrostat acquisition

• AstraZeneca acquired baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. 
• A contingent value right of $10 per share in cash ($0.5 billion) is payable to former CinCor shareholders upon the submission of a new drug application either in the US or Europe.

The Cardiovascular, renal and Metabolism

• Cardiovascular, renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. 
• By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. 
• The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!